Population Pharmacokinetics of Allopurinol in Full-Term Neonates With Perinatal Asphyxia
Authors:
- Charlotte van KesterenCKCharlotte van Kesteren
- Manon J. N. L. BendersMBManon J. N. L. Benders
- Floris GroenendaalFGFloris Groenendaal
- Frank van BelFBFrank van Bel
- F. F. Tessa VerversFVF. F. Tessa Ververs
- Carin M. A. RademakerCRCarin M. A. Rademaker
- 1 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 28 (3) , 339-344
Abstract
In newborn infants, allopurinol is being tested as a free radical scavenger to prevent brain damage caused by reperfusion and oxygenation after perinatal hypoxia and ischemia (birth asphyxia). To develop rational dosing schemes for future studies, knowledge of the pharmacokinetics in this patient group is essential. In the present study, a population pharmacokinetic model was designed and validated for allopurinol in this specific patient group. One-compartment and 2-compartment models were fitted to plasma concentration time data of 24 newborns entered in 2 clinical trials using nonlinear mixed effects modeling. A bootstrap procedure was performed to check the robustness of the model. The data were best described using a 1-compartment model with linear elimination. Estimated pharmacokinetic parameters were volume of the central compartment (V, 0.79 L/kg) and total body clearance (CL, 0.078 L/h/kg), with 42% and 60% interindividual variability, respectively. The median values for these parameters of 1000 bootstrap replicates were very similar (95% confidence intervals were 0.67 to 0.96 and 0.054 to 0.10 for V and CL, respectively), indicating the robustness of the model. A population pharmacokinetic model has been designed and validated which adequately describes the data of 2 clinical studies in critically ill newborn infants. The model will be used to design dosing strategies for future evaluation of the benefits of allopurinol in these patients.Keywords
This publication has 14 references indexed in Scilit:
- Pharmacotherapeutical Reduction of Post-Hypoxic-Ischemic Brain Injury in the NewbornNeonatology, 2001
- Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjectsBritish Journal of Clinical Pharmacology, 1999
- Statistical Graphics in Pharmacokinetics and Pharmacodynamics: A TutorialAnnals of Pharmacotherapy, 1998
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- New Uses for AllopurinolDrugs, 1994
- Reduction of Perinatal Hypoxic-Ischemic Brain Damage with AllopurinolPediatric Research, 1990
- Clinical Pharmacokinetics of AllopurinolClinical Pharmacokinetics, 1986
- The incidence and severity of post-asphyxial encephalopathy in full-term infantsEarly Human Development, 1985
- Oxygen-Derived Free Radicals in Postischemic Tissue InjuryNew England Journal of Medicine, 1985
- Severe allopurinol toxicityThe American Journal of Medicine, 1984